Insulin transdermal - Phosphagenics

Drug Profile

Insulin transdermal - Phosphagenics

Alternative Names: TPM-02/Insulin; TPM/Insulin

Latest Information Update: 07 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Phosphagenics
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 24 Jul 2013 Biomarkers information updated
  • 13 Apr 2011 Insulin transdermal - Phosphagenics is available for licensing as of 13 Apr 2011. http://www.phosphagenics.com
  • 18 Dec 2009 Phosphagenic updates insulin patch development status
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top